October 29, 2012
by admin
2 Comments
Until 18th October, bardoxolone methyl (Abbott/Reata) and BG-12 (Biogen) had two things in common: the nrf2 transcription factor complex as their molecular target; and their candidacy for blockbuster status. Then Reata halted clinical development of bardoxolone, following an excess of … Continue reading
October 24, 2012
by admin
8 Comments
Some of the most important lessons in life are learned in the playground. And so it proved this week, when more than 100 wannabe biotech entrepreneurs gathered in London for the Playground event organized by Index Ventures and Nature Biotechnology. … Continue reading
October 2, 2012
by admin
0 comments
There was something quite ironic when Luke Timmerman of Xconomy described DrugBaron as “Twitter-savvy”. Even allowing for poetic license that represents a turnaround to match the heroics of the European Ryder Cup golf team last weekend. When it comes to … Continue reading